Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
Illumina and GenoScreen Launch Next Generation Sequencing Innovation to Eliminate Tuberculosis in Africa
Illumina, a global leader in DNA sequencing and array-based technologies, and GenoScreen, an innovative genomics […]
Illumina and Myriad Genetics Expand Partnership to Broaden Access to HRD Testing in the United States
Illumina, a global leader in DNA sequencing and array-based technologies, and Myriad Genetics, a leader […]
Illumina Introduces New Pan-Cancer Companion Diagnostic to Match Patients with Rare Genetic Mutations to Targeted Therapy
Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the […]
Illumina and Allegheny Health Network to Assess In-House Comprehensive Cancer Genomic Profiling to Enhance Patient Care
Illumina, Inc. (NASDAQ: ILMN) a global leader in DNA sequencing and array-based technologies, and Allegheny Health […]
Illumina and Boehringer Ingelheim Announce Companion Diagnostic Partnership
Illumina Inc. (NASDAQ: ILMN) today announced a partnership with Boehringer Ingelheim to develop companion diagnostics (CDx) […]
SomaLogic Announces Exclusive Partnership with Illumina to Develop Sequencing-based Proteomic Solutions
SomaLogic (NASDAQ: SLGC), a leader in data-driven proteomics technology, today announced a worldwide strategic collaboration […]
BICO Announces Appointment of Susan Tousi as New Member of the Board of Directors
Today BICO, the world’s leading Bio Convergence company announced it has added Susan Tousi to […]
Whole Genome Sequencing Improves Diagnosis of Rare Diseases and Shortens Diagnostic Journeys for Patients, According to World First Study
A world-first scientific study, published today in the New England Journal of Medicine, has shown that […]
Illumina Appoints Bob Ragusa as Chief Executive Officer (CEO) of GRAIL
Illumina, Inc. (NASDAQ:ILMN) today announced that Bob Ragusa has been appointed as Chief Executive Officer of GRAIL, […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more